{
  "DOI": "10.1186/s40246-023-00507-2",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-023-00507-2",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eThis review discusses the discovery, epidemiology, pathophysiology, genetic etiology, molecular diagnosis, and medication-based management of fragile X syndrome (FXS). It also highlights the syndrome’s variable expressivity and common comorbid and overlapping conditions. FXS is an X-linked dominant disorder associated with a wide spectrum of clinical features, including but not limited to intellectual disability, autism spectrum disorder, language deficits, macroorchidism, seizures, and anxiety. Its prevalence in the general population is approximately 1 in 5000–7000 men and 1 in 4000–6000 women worldwide. FXS is associated with the \u003cjats:italic\u003efragile X messenger ribonucleoprotein 1\u003c/jats:italic\u003e (\u003cjats:italic\u003eFMR1\u003c/jats:italic\u003e) gene located at locus Xq27.3 and encodes the fragile X messenger ribonucleoprotein (FMRP). Most individuals with FXS have an \u003cjats:italic\u003eFMR1\u003c/jats:italic\u003e allele with \u0026gt; 200 CGG repeats (full mutation) and hypermethylation of the CpG island proximal to the repeats, which silences the gene’s promoter. Some individuals have mosaicism in the size of the CGG repeats or in hypermethylation of the CpG island, both produce some FMRP and give rise to milder cognitive and behavioral deficits than in non-mosaic individuals with FXS. As in several monogenic disorders, modifier genes influence the penetrance of \u003cjats:italic\u003eFMR1\u003c/jats:italic\u003e mutations and FXS’s variable expressivity by regulating the pathophysiological mechanisms related to the syndrome’s behavioral features. Although there is no cure for FXS, prenatal molecular diagnostic testing is recommended to facilitate early diagnosis. Pharmacologic agents can reduce some behavioral features of FXS, and researchers are investigating whether gene editing can be used to demethylate the FMR1 promoter region to improve patient outcomes. Moreover, clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 and developed nuclease defective Cas9 (dCas9) strategies have promised options of genome editing in gain-of-function mutations to rewrite new genetic information into a specified DNA site, are also being studied.\u003c/jats:p\u003e",
  "alternative-id": [
    "507"
  ],
  "article-number": "60",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "21 March 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "3 July 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "7 July 2023"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "This work was approved by the Institutional Biomedical Ethics Committee of Umm Al-Qura University under the declaration of the National Committee of Biomedical Ethics at King Abdulaziz City for Sciences and Technology (KACST) (ExternalRef removed)."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Written informed consent was obtained from the parents of all study participants to publish the results."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "The authors declare that they have no competing interests."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-9137-351X",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Elhawary",
      "given": "Nasser A.",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "AlJahdali",
      "given": "Imad A.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Abumansour",
      "given": "Iman S.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Azher",
      "given": "Zohor A.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Falemban",
      "given": "Alaa H.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Madani",
      "given": "Wefaq M.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Alosaimi",
      "given": "Wafaa",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Alghamdi",
      "given": "Ghydda",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Sindi",
      "given": "Ikhlas A.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ],
    "date-time": "2023-07-07T13:01:53Z",
    "timestamp": 1688734913000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ],
    "date-time": "2023-07-07T13:07:44Z",
    "timestamp": 1688735264000
  },
  "funder": [
    {
      "award": [
        "23-MED-01",
        "23-MED-01"
      ],
      "name": "This work was technically and financially supported by the Batterjee Medical College, Jeddah, Saudi Arabia for publishing this work."
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        19
      ]
    ],
    "date-time": "2024-04-19T11:27:58Z",
    "timestamp": 1713526078622
  },
  "is-referenced-by-count": 2,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2023,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            7,
            7
          ]
        ],
        "date-time": "2023-07-07T00:00:00Z",
        "timestamp": 1688688000000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            7,
            7
          ]
        ],
        "date-time": "2023-07-07T00:00:00Z",
        "timestamp": 1688688000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00507-2.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-023-00507-2/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00507-2.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1002/ajmg.a.36511",
      "author": "J Hunter",
      "doi-asserted-by": "publisher",
      "first-page": "1648",
      "issue": "7",
      "journal-title": "Am J Med Genet A",
      "key": "507_CR1",
      "unstructured": "Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet A. 2014;164A(7):1648–58.",
      "volume": "164A",
      "year": "2014"
    },
    {
      "DOI": "10.56021/9780801868436",
      "doi-asserted-by": "crossref",
      "key": "507_CR2",
      "unstructured": "Hagerman RJ. Fragile X syndrome: diagnosis, treatment and research. In: Hagerman RJ, Hagerman PJ (eds) 3–109 (Johns Hopkins Univ. Press, 2002)."
    },
    {
      "DOI": "10.1111/jar.12272",
      "author": "W Saldarriaga",
      "doi-asserted-by": "publisher",
      "first-page": "970",
      "issue": "5",
      "journal-title": "J Appl Res Intellect Disabil",
      "key": "507_CR3",
      "unstructured": "Saldarriaga W, Ruiz FA, Tassone F, Hagerman R. Down syndrome and fragile X syndrome in a Colombian woman: case report. J Appl Res Intellect Disabil. 2017;30(5):970–4.",
      "volume": "30",
      "year": "2017"
    },
    {
      "DOI": "10.1016/0092-8674(91)90397-H",
      "author": "AJ Verkerk",
      "doi-asserted-by": "publisher",
      "first-page": "905",
      "issue": "5",
      "journal-title": "Cell",
      "key": "507_CR4",
      "unstructured": "Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–14.",
      "volume": "65",
      "year": "1991"
    },
    {
      "DOI": "10.1172/JCI63141",
      "author": "C Bagni",
      "doi-asserted-by": "publisher",
      "first-page": "4314",
      "issue": "12",
      "journal-title": "J Clin Invest",
      "key": "507_CR5",
      "unstructured": "Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012;122(12):4314–22.",
      "volume": "122",
      "year": "2012"
    },
    {
      "DOI": "10.3390/ijms21124391",
      "doi-asserted-by": "crossref",
      "key": "507_CR6",
      "unstructured": "Cabal-Herrera AM, Tassanakijpanich N, Salcedo-Arellano MJ, Hagerman RJ. Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): pathophysiology and clinical implications. Int J Mol Sci. 2020;21(12)."
    },
    {
      "DOI": "10.1007/s12311-021-01323-x",
      "author": "Y Higuchi",
      "doi-asserted-by": "publisher",
      "first-page": "851",
      "issue": "5",
      "journal-title": "Cerebellum",
      "key": "507_CR7",
      "unstructured": "Higuchi Y, Ando M, Yoshimura A, Hakotani S, Koba Y, Sakiyama Y, Hiramatsu Y, Tashiro Y, Maki Y, Hashiguchi A, et al. Prevalence of fragile X-associated tremor/ataxia syndrome in patients with cerebellar ataxia in Japan. Cerebellum. 2022;21(5):851–60.",
      "volume": "21",
      "year": "2022"
    },
    {
      "DOI": "10.1186/1866-1955-6-26",
      "author": "SL Sherman",
      "doi-asserted-by": "publisher",
      "first-page": "26",
      "issue": "1",
      "journal-title": "J Neurodev Disord",
      "key": "507_CR8",
      "unstructured": "Sherman SL, Curnow EC, Easley CA, Jin P, Hukema RK, Tejada MI, Willemsen R, Usdin K. Use of model systems to understand the etiology of fragile X-associated primary ovarian insufficiency (FXPOI). J Neurodev Disord. 2014;6(1):26.",
      "volume": "6",
      "year": "2014"
    },
    {
      "DOI": "10.1007/s10803-016-2737-1",
      "author": "JE Roberts",
      "doi-asserted-by": "publisher",
      "first-page": "2088",
      "issue": "6",
      "journal-title": "J Autism Dev Disord",
      "key": "507_CR9",
      "unstructured": "Roberts JE, McCary LM, Shinkareva SV, Bailey DB Jr. Infant development in fragile X syndrome: cross-syndrome comparisons. J Autism Dev Disord. 2016;46(6):2088–99.",
      "volume": "46",
      "year": "2016"
    },
    {
      "DOI": "10.1371/journal.pone.0021728",
      "author": "CM Yrigollen",
      "doi-asserted-by": "publisher",
      "first-page": "e21728",
      "issue": "7",
      "journal-title": "PLoS ONE",
      "key": "507_CR10",
      "unstructured": "Yrigollen CM, Tassone F, Durbin-Johnson B, Tassone F. The role of AGG interruptions in the transcription of FMR1 premutation alleles. PLoS ONE. 2011;6(7):e21728.",
      "volume": "6",
      "year": "2011"
    },
    {
      "DOI": "10.1002/ajmg.a.35833",
      "author": "SL Nolin",
      "doi-asserted-by": "publisher",
      "first-page": "771",
      "issue": "4",
      "journal-title": "Am J Med Genet A",
      "key": "507_CR11",
      "unstructured": "Nolin SL, Sah S, Glicksman A, Sherman SL, Allen E, Berry-Kravis E, Tassone F, Yrigollen C, Cronister A, Jodah M, et al. Fragile X AGG analysis provides new risk predictions for 45–69 repeat alleles. Am J Med Genet A. 2013;161A(4):771–8.",
      "volume": "161A",
      "year": "2013"
    },
    {
      "DOI": "10.1186/gm401",
      "author": "F Tassone",
      "doi-asserted-by": "publisher",
      "first-page": "100",
      "issue": "12",
      "journal-title": "Genome Med",
      "key": "507_CR12",
      "unstructured": "Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, Nguyen D, Mu LY, Laffin J, Bailey DB, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):100.",
      "volume": "4",
      "year": "2012"
    },
    {
      "DOI": "10.5582/irdr.2016.01045",
      "author": "A Ligsay",
      "doi-asserted-by": "publisher",
      "first-page": "158",
      "issue": "3",
      "journal-title": "Intractable Rare Dis Res",
      "key": "507_CR13",
      "unstructured": "Ligsay A, Hagerman RJ. Review of targeted treatments in fragile X syndrome. Intractable Rare Dis Res. 2016;5(3):158–67.",
      "volume": "5",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nrdp.2017.65",
      "author": "RJ Hagerman",
      "doi-asserted-by": "publisher",
      "first-page": "17065",
      "journal-title": "Nat Rev Dis Primers",
      "key": "507_CR14",
      "unstructured": "Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB Jr, Moine H, Kooy RF, Tassone F, Gantois I, Sonenberg N, Mandel JL, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065.",
      "volume": "3",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.nbd.2020.104740",
      "author": "MJ Salcedo-Arellano",
      "doi-asserted-by": "publisher",
      "first-page": "104740",
      "journal-title": "Neurobiol Dis",
      "key": "507_CR15",
      "unstructured": "Salcedo-Arellano MJ, Dufour B, McLennan Y, Martinez-Cerdeno V, Hagerman R. Fragile X syndrome and associated disorders: Clinical aspects and pathology. Neurobiol Dis. 2020;136:104740.",
      "volume": "136",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41583-021-00445-9",
      "author": "PY Deng",
      "doi-asserted-by": "publisher",
      "first-page": "275",
      "issue": "5",
      "journal-title": "Nat Rev Neurosci",
      "key": "507_CR16",
      "unstructured": "Deng PY, Klyachko VA. Channelopathies in fragile X syndrome. Nat Rev Neurosci. 2021;22(5):275–89.",
      "volume": "22",
      "year": "2021"
    },
    {
      "DOI": "10.1038/emm.2017.10",
      "author": "M Kim",
      "doi-asserted-by": "publisher",
      "first-page": "e322",
      "issue": "4",
      "journal-title": "Exp Mol Med",
      "key": "507_CR17",
      "unstructured": "Kim M, Costello J. DNA methylation: an epigenetic mark of cellular memory. Exp Mol Med. 2017;49(4):e322.",
      "volume": "49",
      "year": "2017"
    },
    {
      "DOI": "10.1111/dmcn.13985",
      "author": "CM Kraan",
      "doi-asserted-by": "publisher",
      "first-page": "121",
      "issue": "2",
      "journal-title": "Dev Med Child Neurol",
      "key": "507_CR18",
      "unstructured": "Kraan CM, Godler DE, Amor DJ. Epigenetics of fragile X syndrome and fragile X-related disorders. Dev Med Child Neurol. 2019;61(2):121–7.",
      "volume": "61",
      "year": "2019"
    },
    {
      "DOI": "10.1016/0092-8674(91)90125-I",
      "author": "M Pieretti",
      "doi-asserted-by": "publisher",
      "first-page": "817",
      "issue": "4",
      "journal-title": "Cell",
      "key": "507_CR19",
      "unstructured": "Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817–22.",
      "volume": "66",
      "year": "1991"
    },
    {
      "DOI": "10.1111/j.1528-1157.1999.tb00824.x",
      "author": "SA Musumeci",
      "doi-asserted-by": "publisher",
      "first-page": "1092",
      "issue": "8",
      "journal-title": "Epilepsia",
      "key": "507_CR20",
      "unstructured": "Musumeci SA, Hagerman RJ, Ferri R, Bosco P, Dalla Bernardina B, Tassinari CA, De Sarro GB, Elia M. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia. 1999;40(8):1092–9.",
      "volume": "40",
      "year": "1999"
    },
    {
      "DOI": "10.1001/jamaneurol.2013.4808",
      "author": "F Tassone",
      "doi-asserted-by": "publisher",
      "first-page": "355",
      "issue": "3",
      "journal-title": "JAMA Neurol",
      "key": "507_CR21",
      "unstructured": "Tassone F. Newborn screening for fragile X syndrome. JAMA Neurol. 2014;71(3):355–9.",
      "volume": "71",
      "year": "2014"
    },
    {
      "DOI": "10.1007/s11940-019-0551-8",
      "author": "I Jalnapurkar",
      "doi-asserted-by": "publisher",
      "first-page": "12",
      "issue": "3",
      "journal-title": "Curr Treat Options Neurol",
      "key": "507_CR22",
      "unstructured": "Jalnapurkar I, Cochran DM, Frazier JA. New therapeutic options for fragile X syndrome. Curr Treat Options Neurol. 2019;21(3):12.",
      "volume": "21",
      "year": "2019"
    },
    {
      "DOI": "10.3390/brainsci13020277",
      "doi-asserted-by": "crossref",
      "key": "507_CR23",
      "unstructured": "Montanaro FAM, Alfieri P, Vicari S. \"Corp-Osa-Mente\", a Combined psychosocial-neuropsychological intervention for adolescents and young adults with fragile X syndrome: an explorative study. Brain Sci. 2023;13(2)."
    },
    {
      "DOI": "10.1136/jnnp.6.3-4.154",
      "author": "JP Martin",
      "doi-asserted-by": "publisher",
      "first-page": "154",
      "issue": "3–4",
      "journal-title": "J Neurol Psychiatry",
      "key": "507_CR24",
      "unstructured": "Martin JP, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry. 1943;6(3–4):154–7.",
      "volume": "6",
      "year": "1943"
    },
    {
      "author": "HA Lubs",
      "first-page": "231",
      "issue": "3",
      "journal-title": "Am J Hum Genet",
      "key": "507_CR25",
      "unstructured": "Lubs HA. A marker X chromosome. Am J Hum Genet. 1969;21(3):231–44.",
      "volume": "21",
      "year": "1969"
    },
    {
      "author": "JA Escalante",
      "first-page": "137",
      "issue": "2",
      "journal-title": "J Genet Hum",
      "key": "507_CR26",
      "unstructured": "Escalante JA, Grunspun H, Frota-Pessoa O. Severe sex-linked mental retardation. J Genet Hum. 1971;19(2):137–40.",
      "volume": "19",
      "year": "1971"
    },
    {
      "DOI": "10.1007/s004390050495",
      "author": "SM Klauck",
      "doi-asserted-by": "publisher",
      "first-page": "224",
      "issue": "2",
      "journal-title": "Hum Genet",
      "key": "507_CR27",
      "unstructured": "Klauck SM, Munstermann E, Bieber-Martig B, Ruhl D, Lisch S, Schmotzer G, Poustka A, Poustka F. Molecular genetic analysis of the FMR-1 gene in a large collection of autistic patients. Hum Genet. 1997;100(2):224–9.",
      "volume": "100",
      "year": "1997"
    },
    {
      "DOI": "10.1007/s13311-015-0355-9",
      "author": "C Gross",
      "doi-asserted-by": "publisher",
      "first-page": "584",
      "issue": "3",
      "journal-title": "Neurotherapeutics",
      "key": "507_CR28",
      "unstructured": "Gross C, Hoffmann A, Bassell GJ, Berry-Kravis EM. Therapeutic strategies in fragile X syndrome: from bench to bedside and back. Neurotherapeutics. 2015;12(3):584–608.",
      "volume": "12",
      "year": "2015"
    },
    {
      "DOI": "10.1093/hmg/11.4.371",
      "author": "C Dombrowski",
      "doi-asserted-by": "publisher",
      "first-page": "371",
      "issue": "4",
      "journal-title": "Hum Mol Genet",
      "key": "507_CR29",
      "unstructured": "Dombrowski C, Levesque S, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet. 2002;11(4):371–8.",
      "volume": "11",
      "year": "2002"
    },
    {
      "DOI": "10.1016/j.ajhg.2009.09.007",
      "author": "B Coffee",
      "doi-asserted-by": "publisher",
      "first-page": "503",
      "issue": "4",
      "journal-title": "Am J Hum Genet",
      "key": "507_CR30",
      "unstructured": "Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85(4):503–14.",
      "volume": "85",
      "year": "2009"
    },
    {
      "DOI": "10.1111/j.1399-0004.2009.01237.x",
      "author": "S Levesque",
      "doi-asserted-by": "publisher",
      "first-page": "511",
      "issue": "6",
      "journal-title": "Clin Genet",
      "key": "507_CR31",
      "unstructured": "Levesque S, Dombrowski C, Morel ML, Rehel R, Cote JS, Bussieres J, Morgan K, Rousseau F. Screening and instability of FMR1 alleles in a prospective sample of 24,449 mother-newborn pairs from the general population. Clin Genet. 2009;76(6):511–23.",
      "volume": "76",
      "year": "2009"
    },
    {
      "DOI": "10.1038/jhg.2016.122",
      "author": "N Maia",
      "doi-asserted-by": "publisher",
      "first-page": "269",
      "issue": "2",
      "journal-title": "J Hum Genet",
      "key": "507_CR32",
      "unstructured": "Maia N, Loureiro JR, Oliveira B, Marques I, Santos R, Jorge P, Martins S. Contraction of fully expanded FMR1 alleles to the normal range: predisposing haplotype or rare events? J Hum Genet. 2017;62(2):269–75.",
      "volume": "62",
      "year": "2017"
    },
    {
      "DOI": "10.1017/S0016672316000082",
      "author": "L Santa Maria",
      "doi-asserted-by": "publisher",
      "journal-title": "Genet Res (Camb)",
      "key": "507_CR33",
      "unstructured": "Santa Maria L, Aliaga S, Faundes V, Morales P, Pugin A, Curotto B, Soto P, Pena MI, Salas I, Alliende MA. FMR1 gene mutations in patients with fragile X syndrome and obligate carriers: 30 years of experience in Chile. Genet Res (Camb). 2016;98: e11.",
      "volume": "98",
      "year": "2016"
    },
    {
      "DOI": "10.1089/109065703322783725",
      "author": "M Rife",
      "doi-asserted-by": "publisher",
      "first-page": "339",
      "issue": "4",
      "journal-title": "Genet Test",
      "key": "507_CR34",
      "unstructured": "Rife M, Badenas C, Mallolas J, Jimenez L, Cervera R, Maya A, Glover G, Rivera F, Mila M. Incidence of fragile X in 5,000 consecutive newborn males. Genet Test. 2003;7(4):339–43.",
      "volume": "7",
      "year": "2003"
    },
    {
      "DOI": "10.2353/jmoldx.2009.080173",
      "author": "I Fernandez-Carvajal",
      "doi-asserted-by": "publisher",
      "first-page": "324",
      "issue": "4",
      "journal-title": "J Mol Diagn",
      "key": "507_CR35",
      "unstructured": "Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009;11(4):324–9.",
      "volume": "11",
      "year": "2009"
    },
    {
      "DOI": "10.1155/2014/195793",
      "author": "MI Tejada",
      "doi-asserted-by": "publisher",
      "first-page": "195793",
      "journal-title": "Biomed Res Int",
      "key": "507_CR36",
      "unstructured": "Tejada MI, Glover G, Martinez F, Guitart M, de Diego-Otero Y, Fernandez-Carvajal I, Ramos FJ, Hernandez-Chico C, Pintado E, Rosell J, et al. Molecular testing for fragile X: analysis of 5062 tests from 1105 fragile X families–performed in 12 clinical laboratories in Spain. Biomed Res Int. 2014;2014:195793.",
      "volume": "2014",
      "year": "2014"
    },
    {
      "DOI": "10.1038/s10038-017-0407-6",
      "author": "W Saldarriaga",
      "doi-asserted-by": "publisher",
      "first-page": "509",
      "issue": "4",
      "journal-title": "J Hum Genet",
      "key": "507_CR37",
      "unstructured": "Saldarriaga W, Forero-Forero JV, Gonzalez-Teshima LY, Fandino-Losada A, Isaza C, Tovar-Cuevas JR, Silva M, Choudhary NS, Tang HT, Aguilar-Gaxiola S, et al. Genetic cluster of fragile X syndrome in a Colombian district. J Hum Genet. 2018;63(4):509–16.",
      "volume": "63",
      "year": "2018"
    },
    {
      "author": "B Gerard",
      "first-page": "139",
      "issue": "3",
      "journal-title": "Ann Genet",
      "key": "507_CR38",
      "unstructured": "Gerard B, Le Heuzey MF, Brunie G, Lewine P, Saiag MC, Cacheux V, Da Silva F, Dugas M, Mouren-Simeoni MC, Elion J, et al. Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children. Ann Genet. 1997;40(3):139–44.",
      "volume": "40",
      "year": "1997"
    },
    {
      "DOI": "10.1016/j.ejmg.2009.03.014",
      "author": "AR Pouya",
      "doi-asserted-by": "publisher",
      "first-page": "170",
      "issue": "4",
      "journal-title": "Eur J Med Genet",
      "key": "507_CR39",
      "unstructured": "Pouya AR, Abedini SS, Mansoorian N, Behjati F, Nikzat N, Mohseni M, Nieh SE, Abbasi Moheb L, Darvish H, Monajemi GB, et al. Fragile X syndrome screening of families with consanguineous and non-consanguineous parents in the Iranian population. Eur J Med Genet. 2009;52(4):170–3.",
      "volume": "52",
      "year": "2009"
    },
    {
      "DOI": "10.1007/s12519-021-00473-6",
      "author": "JY Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "653",
      "issue": "6",
      "journal-title": "World J Pediatr",
      "key": "507_CR40",
      "unstructured": "Zhang JY, Wu DW, Yang RL, Zhu L, Jiang MY, Wang WJ, Li XK, Jiang XL, Tong F, Shu Q. FMR1 allele frequencies in 51,000 newborns: a large-scale population study in China. World J Pediatr. 2021;17(6):653–8.",
      "volume": "17",
      "year": "2021"
    },
    {
      "author": "P Limprasert",
      "first-page": "114",
      "issue": "Suppl 2",
      "journal-title": "Southeast Asian J Trop Med Public Health",
      "key": "507_CR41",
      "unstructured": "Limprasert P, Ruangdaraganon N, Sura T, Vasiknanonte P, Jinorose U. Molecular screening for fragile X syndrome in Thailand. Southeast Asian J Trop Med Public Health. 1999;30(Suppl 2):114–8.",
      "volume": "30",
      "year": "1999"
    },
    {
      "DOI": "10.5582/irdr.2020.03101",
      "author": "NRB Sihombing",
      "doi-asserted-by": "publisher",
      "first-page": "11",
      "issue": "1",
      "journal-title": "Intractable Rare Dis Res",
      "key": "507_CR42",
      "unstructured": "Sihombing NRB, Winarni TI, Utari A, van Bokhoven H, Hagerman RJ, Faradz SM. Surveillance and prevalence of fragile X syndrome in Indonesia. Intractable Rare Dis Res. 2021;10(1):11–6.",
      "volume": "10",
      "year": "2021"
    },
    {
      "author": "EZ Ali",
      "first-page": "99",
      "issue": "2",
      "journal-title": "Malays J Pathol",
      "key": "507_CR43",
      "unstructured": "Ali EZ, Yakob Y, Md Desa N, Ishak T, Zakaria Z, Ngu LK, Keng WT. Molecular analysis of fragile X syndrome (FXS) among Malaysian patients with developmental disability. Malays J Pathol. 2017;39(2):99–106.",
      "volume": "39",
      "year": "2017"
    },
    {
      "DOI": "10.1111/j.1365-2788.2009.01176.x",
      "author": "I Mirza",
      "doi-asserted-by": "publisher",
      "first-page": "559",
      "issue": "6",
      "journal-title": "J Intellect Disabil Res",
      "key": "507_CR44",
      "unstructured": "Mirza I, Tareen A, Davidson LL, Rahman A. Community management of intellectual disabilities in Pakistan: a mixed methods study. J Intellect Disabil Res. 2009;53(6):559–70.",
      "volume": "53",
      "year": "2009"
    },
    {
      "author": "L Ben Jemaa",
      "first-page": "973",
      "issue": "11",
      "journal-title": "Tunis Med",
      "key": "507_CR45",
      "unstructured": "Ben Jemaa L, Khemir S, Maazoul F, Richard L, Beldjord C, Chaabouni M, Chaabouni H. Molecular diagnosis of fragile X syndrome. Tunis Med. 2008;86(11):973–7.",
      "volume": "86",
      "year": "2008"
    },
    {
      "DOI": "10.3389/fnmol.2017.00290",
      "author": "L Man",
      "doi-asserted-by": "publisher",
      "first-page": "290",
      "journal-title": "Front Mol Neurosci",
      "key": "507_CR46",
      "unstructured": "Man L, Lekovich J, Rosenwaks Z, Gerhardt J. Fragile X-associated diminished ovarian reserve and primary ovarian insufficiency from molecular mechanisms to clinical manifestations. Front Mol Neurosci. 2017;10:290.",
      "volume": "10",
      "year": "2017"
    },
    {
      "DOI": "10.5144/0256-4947.2000.16",
      "author": "M Al Husain",
      "doi-asserted-by": "publisher",
      "first-page": "16",
      "issue": "1",
      "journal-title": "Ann Saudi Med",
      "key": "507_CR47",
      "unstructured": "Al Husain M, Salih MA, Zaki OK, Al Othman L, Al Nasser MN. A clinical study of mentally retarded children with fragile X syndrome in Saudi Arabia. Ann Saudi Med. 2000;20(1):16–9.",
      "volume": "20",
      "year": "2000"
    },
    {
      "DOI": "10.1007/s11845-022-03166-9",
      "doi-asserted-by": "crossref",
      "key": "507_CR48",
      "unstructured": "Refeat MM, El Saied MM, Abdel Raouf ER. Diagnostic value of molecular approach in screening for fragile X premutation cases. Ir J Med Sci. 2022."
    },
    {
      "DOI": "10.1002/(SICI)1096-8628(20000605)92:4\u003c229::AID-AJMG1\u003e3.0.CO;2-K",
      "author": "AM Lachiewicz",
      "doi-asserted-by": "publisher",
      "first-page": "229",
      "issue": "4",
      "journal-title": "Am J Med Genet",
      "key": "507_CR49",
      "unstructured": "Lachiewicz AM, Dawson DV, Spiridigliozzi GA. Physical characteristics of young boys with fragile X syndrome: reasons for difficulties in making a diagnosis in young males. Am J Med Genet. 2000;92(4):229–36.",
      "volume": "92",
      "year": "2000"
    },
    {
      "author": "RJ Hagerman",
      "key": "507_CR50",
      "unstructured": "Hagerman RJ, Hagerman PJ. Fragile X syndrome and premutation disorders. London: Mac Keith Press; 2020.",
      "volume-title": "Fragile X syndrome and premutation disorders",
      "year": "2020"
    },
    {
      "DOI": "10.1038/ejhg.2012.265",
      "author": "I Heulens",
      "doi-asserted-by": "publisher",
      "first-page": "816",
      "issue": "8",
      "journal-title": "Eur J Hum Genet",
      "key": "507_CR51",
      "unstructured": "Heulens I, Suttie M, Postnov A, De Clerck N, Perrotta CS, Mattina T, Faravelli F, Forzano F, Kooy RF, Hammond P. Craniofacial characteristics of fragile X syndrome in mouse and man. Eur J Hum Genet. 2013;21(8):816–23.",
      "volume": "21",
      "year": "2013"
    },
    {
      "DOI": "10.1155/2017/9318346",
      "author": "C Charalsawadi",
      "doi-asserted-by": "publisher",
      "first-page": "9318346",
      "journal-title": "Int J Pediatr",
      "key": "507_CR52",
      "unstructured": "Charalsawadi C, Wirojanan J, Jaruratanasirikul S, Ruangdaraganon N, Geater A, Limprasert P. Common clinical characteristics and rare medical problems of fragile X syndrome in Thai patients and review of the literature. Int J Pediatr. 2017;2017:9318346.",
      "volume": "2017",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s13052-017-0355-y",
      "author": "C Ciaccio",
      "doi-asserted-by": "publisher",
      "first-page": "39",
      "issue": "1",
      "journal-title": "Ital J Pediatr",
      "key": "507_CR53",
      "unstructured": "Ciaccio C, Fontana L, Milani D, Tabano S, Miozzo M, Esposito S. Fragile X syndrome: a review of clinical and molecular diagnoses. Ital J Pediatr. 2017;43(1):39.",
      "volume": "43",
      "year": "2017"
    },
    {
      "author": "MJ Salcedo-Arellano",
      "first-page": "60",
      "issue": "1",
      "journal-title": "Gac Med Mex",
      "key": "507_CR54",
      "unstructured": "Salcedo-Arellano MJ, Hagerman RJ, Martinez-Cerdeno V. Fragile X syndrome: clinical presentation, pathology and treatment. Gac Med Mex. 2020;156(1):60–6.",
      "volume": "156",
      "year": "2020"
    },
    {
      "DOI": "10.1542/peds.2008-2992",
      "author": "DB Bailey Jr",
      "doi-asserted-by": "publisher",
      "first-page": "527",
      "issue": "2",
      "journal-title": "Pediatrics",
      "key": "507_CR55",
      "unstructured": "Bailey DB Jr, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey. Pediatrics. 2009;124(2):527–33.",
      "volume": "124",
      "year": "2009"
    },
    {
      "DOI": "10.1017/S0954579420000942",
      "author": "JE Roberts",
      "doi-asserted-by": "publisher",
      "first-page": "1335",
      "issue": "4",
      "journal-title": "Dev Psychopathol",
      "key": "507_CR56",
      "unstructured": "Roberts JE, Bradshaw J, Will E, Hogan AL, McQuillin S, Hills K. Emergence and rate of autism in fragile X syndrome across the first years of life. Dev Psychopathol. 2020;32(4):1335–52.",
      "volume": "32",
      "year": "2020"
    },
    {
      "DOI": "10.1002/(SICI)1096-8628(19990402)83:4\u003c286::AID-AJMG10\u003e3.0.CO;2-H",
      "author": "WE Kaufmann",
      "doi-asserted-by": "publisher",
      "first-page": "286",
      "issue": "4",
      "journal-title": "Am J Med Genet",
      "key": "507_CR57",
      "unstructured": "Kaufmann WE, Abrams MT, Chen W, Reiss AL. Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. Am J Med Genet. 1999;83(4):286–95.",
      "volume": "83",
      "year": "1999"
    },
    {
      "DOI": "10.12688/f1000research.11885.1",
      "author": "A Rajaratnam",
      "doi-asserted-by": "publisher",
      "first-page": "2112",
      "journal-title": "F1000Res",
      "key": "507_CR58",
      "unstructured": "Rajaratnam A, Shergill J, Salcedo-Arellano M, Saldarriaga W, Duan X, Hagerman R. Fragile X syndrome and fragile X-associated disorders. F1000Res. 2017;6:2112.",
      "volume": "6",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ijdevneu.2014.07.002",
      "author": "TT Heard",
      "doi-asserted-by": "publisher",
      "first-page": "155",
      "journal-title": "Int J Dev Neurosci",
      "key": "507_CR59",
      "unstructured": "Heard TT, Ramgopal S, Picker J, Lincoln SA, Rotenberg A, Kothare SV. EEG abnormalities and seizures in genetically diagnosed Fragile X syndrome. Int J Dev Neurosci. 2014;38:155–60.",
      "volume": "38",
      "year": "2014"
    },
    {
      "DOI": "10.5582/irdr.2016.01048",
      "author": "R Lozano",
      "doi-asserted-by": "publisher",
      "first-page": "145",
      "issue": "3",
      "journal-title": "Intractable Rare Dis Res",
      "key": "507_CR60",
      "unstructured": "Lozano R, Azarang A, Wilaisakditipakorn T, Hagerman RJ. Fragile X syndrome: A review of clinical management. Intractable Rare Dis Res. 2016;5(3):145–57.",
      "volume": "5",
      "year": "2016"
    },
    {
      "DOI": "10.3389/fnmol.2018.00041",
      "author": "R Dahlhaus",
      "doi-asserted-by": "publisher",
      "first-page": "41",
      "journal-title": "Front Mol Neurosci",
      "key": "507_CR61",
      "unstructured": "Dahlhaus R. Of men and mice: modeling the fragile X syndrome. Front Mol Neurosci. 2018;11:41.",
      "volume": "11",
      "year": "2018"
    },
    {
      "author": "NA Meguid",
      "first-page": "74",
      "issue": "1",
      "journal-title": "Brain Cogn",
      "key": "507_CR62",
      "unstructured": "Meguid NA, Fahim C, Sami R, Nashaat NH, Yoon U, Anwar M, El-Dessouky HM, Shahine EA, Ibrahim AS, Mancini-Marie A, et al. Cognition and lobar morphology in full mutation boys with fragile X syndrome. Brain Cogn. 2012;78(1):74–84.",
      "volume": "78",
      "year": "2012"
    },
    {
      "DOI": "10.1159/000330213",
      "author": "DB Budimirovic",
      "doi-asserted-by": "publisher",
      "first-page": "379",
      "issue": "5",
      "journal-title": "Dev Neurosci",
      "key": "507_CR63",
      "unstructured": "Budimirovic DB, Kaufmann WE. What can we learn about autism from studying fragile X syndrome? Dev Neurosci. 2011;33(5):379–94.",
      "volume": "33",
      "year": "2011"
    },
    {
      "DOI": "10.1186/s11689-017-9193-x",
      "author": "DB Budimirovic",
      "doi-asserted-by": "publisher",
      "first-page": "14",
      "journal-title": "J Neurodev Disord",
      "key": "507_CR64",
      "unstructured": "Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, King MK, Abbeduto L, Kaufmann WE. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. J Neurodev Disord. 2017;9:14.",
      "volume": "9",
      "year": "2017"
    },
    {
      "DOI": "10.1542/peds.2016-1159F",
      "author": "WE Kaufmann",
      "doi-asserted-by": "publisher",
      "first-page": "S194",
      "issue": "Suppl 3",
      "journal-title": "Pediatrics",
      "key": "507_CR65",
      "unstructured": "Kaufmann WE, Kidd SA, Andrews HF, Budimirovic DB, Esler A, Haas-Givler B, Stackhouse T, Riley C, Peacock G, Sherman SL, et al. Autism spectrum disorder in fragile X syndrome: cooccurring conditions and current treatment. Pediatrics. 2017;139(Suppl 3):S194–206.",
      "volume": "139",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ridd.2014.01.032",
      "author": "AJ Thurman",
      "doi-asserted-by": "publisher",
      "first-page": "1072",
      "issue": "5",
      "journal-title": "Res Dev Disabil",
      "key": "507_CR66",
      "unstructured": "Thurman AJ, McDuffie A, Hagerman R, Abbeduto L. Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder. Res Dev Disabil. 2014;35(5):1072–86.",
      "volume": "35",
      "year": "2014"
    },
    {
      "DOI": "10.1542/peds.2016-1159E",
      "author": "SL Sherman",
      "doi-asserted-by": "publisher",
      "first-page": "S183",
      "issue": "Suppl 3",
      "journal-title": "Pediatrics",
      "key": "507_CR67",
      "unstructured": "Sherman SL, Kidd SA, Riley C, Berry-Kravis E, Andrews HF, Miller RM, Lincoln S, Swanson M, Kaufmann WE, Brown WT. FORWARD: A registry and longitudinal clinical database to study fragile X syndrome. Pediatrics. 2017;139(Suppl 3):S183–93.",
      "volume": "139",
      "year": "2017"
    },
    {
      "DOI": "10.1097/DBP.0000000000000850",
      "author": "W Saldarriaga",
      "doi-asserted-by": "publisher",
      "first-page": "724",
      "issue": "9",
      "journal-title": "J Dev Behav Pediatr",
      "key": "507_CR68",
      "unstructured": "Saldarriaga W, Payan-Gomez C, Gonzalez-Teshima LY, Rosa L, Tassone F, Hagerman RJ. Double genetic hit: fragile X syndrome and partial deletion of protein patched homolog 1 antisense as cause of severe autism spectrum disorder. J Dev Behav Pediatr. 2020;41(9):724–8.",
      "volume": "41",
      "year": "2020"
    },
    {
      "DOI": "10.1097/DBP.0000000000000334",
      "author": "L Greiss Hess",
      "doi-asserted-by": "publisher",
      "first-page": "619",
      "issue": "8",
      "journal-title": "J Dev Behav Pediatr",
      "key": "507_CR69",
      "unstructured": "Greiss Hess L, Fitzpatrick SE, Nguyen DV, Chen Y, Gaul KN, Schneider A, Lemons Chitwood K, Eldeeb MA, Polussa J, Hessl D, et al. A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome. J Dev Behav Pediatr. 2016;37(8):619–28.",
      "volume": "37",
      "year": "2016"
    },
    {
      "DOI": "10.1002/ajmg.a.33011",
      "author": "C Dobkin",
      "doi-asserted-by": "publisher",
      "first-page": "2152",
      "issue": "10",
      "journal-title": "Am J Med Genet Part A",
      "key": "507_CR70",
      "unstructured": "Dobkin C, Radu G, Ding X-H, Brown WT, Nolin SL. Fragile X prenatal analyses show full mutation females at high risk for mosaic Turner syndrome: Fragile X leads to chromosome loss. Am J Med Genet Part A. 2009;149A(10):2152–7.",
      "volume": "149A",
      "year": "2009"
    },
    {
      "DOI": "10.1007/s11033-019-04869-6",
      "author": "S Lahbib",
      "doi-asserted-by": "publisher",
      "first-page": "4185",
      "issue": "4",
      "journal-title": "Mol Biol Rep",
      "key": "507_CR71",
      "unstructured": "Lahbib S, Trabelsi M, Dallali H, Sakka R, Bourourou R, Kefi R, Mrad R, Abdelhak S, Gaddour N. Novel MED12 variant in a multiplex Fragile X syndrome family: dual molecular etiology of two X-linked intellectual disabilities with autism in the same family. Mol Biol Rep. 2019;46(4):4185–93.",
      "volume": "46",
      "year": "2019"
    },
    {
      "DOI": "10.1177/08830738050200100201",
      "author": "JY Wu",
      "doi-asserted-by": "publisher",
      "first-page": "790",
      "issue": "10",
      "journal-title": "J Child Neurol",
      "key": "507_CR72",
      "unstructured": "Wu JY, Kuban KC, Allred E, Shapiro F, Darras BT. Association of Duchenne muscular dystrophy with autism spectrum disorder. J Child Neurol. 2005;20(10):790–5.",
      "volume": "20",
      "year": "2005"
    },
    {
      "DOI": "10.1186/s40246-018-0152-8",
      "author": "NA Elhawary",
      "doi-asserted-by": "publisher",
      "first-page": "18",
      "issue": "1",
      "journal-title": "Hum Genom",
      "key": "507_CR73",
      "unstructured": "Elhawary NA, Jiffri EH, Jambi S, Mufti AH, Dannoun A, Kordi H, Khogeer A, Jiffri OH, Elhawary AN, Tayeb MT. Molecular characterization of exonic rearrangements and frame shifts in the dystrophin gene in Duchenne muscular dystrophy patients in a Saudi community. Hum Genom. 2018;12(1):18.",
      "volume": "12",
      "year": "2018"
    },
    {
      "DOI": "10.1007/s12035-019-01845-w",
      "author": "M Naidoo",
      "doi-asserted-by": "publisher",
      "first-page": "1748",
      "issue": "3",
      "journal-title": "Mol Neurobiol",
      "key": "507_CR74",
      "unstructured": "Naidoo M, Anthony K. Dystrophin Dp71 and the neuropathophysiology of Duchenne muscular dystrophy. Mol Neurobiol. 2020;57(3):1748–67.",
      "volume": "57",
      "year": "2020"
    },
    {
      "DOI": "10.3390/genes12121909",
      "doi-asserted-by": "crossref",
      "key": "507_CR75",
      "unstructured": "Tabolacci E, Pomponi MG, Remondini L, Pietrobono R, Orteschi D, Nobile V, Pucci C, Musto E, Pane M, Mercuri EM, et al. Co-occurrence of fragile X syndrome with a second genetic condition: three independent cases of double diagnosis. Genes (Basel). 2021;12(12)."
    },
    {
      "DOI": "10.1007/s12311-016-0809-6",
      "author": "SM Debrey",
      "doi-asserted-by": "publisher",
      "first-page": "623",
      "issue": "5",
      "journal-title": "Cerebellum",
      "key": "507_CR76",
      "unstructured": "Debrey SM, Leehey MA, Klepitskaya O, Filley CM, Shah RC, Kluger B, Berry-Kravis E, Spector E, Tassone F, Hall DA. Clinical phenotype of adult fragile X gray zone allele carriers: a case series. Cerebellum. 2016;15(5):623–31.",
      "volume": "15",
      "year": "2016"
    },
    {
      "DOI": "10.3389/fpsyt.2018.00564",
      "author": "RJ Hagerman",
      "doi-asserted-by": "publisher",
      "first-page": "564",
      "journal-title": "Front Psychiatry",
      "key": "507_CR77",
      "unstructured": "Hagerman RJ, Protic D, Rajaratnam A, Salcedo-Arellano MJ, Aydin EY, Schneider A. Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatry. 2018;9:564.",
      "volume": "9",
      "year": "2018"
    },
    {
      "DOI": "10.2147/TACG.S265835",
      "author": "C Payan-Gomez",
      "doi-asserted-by": "publisher",
      "first-page": "305",
      "journal-title": "Appl Clin Genet",
      "key": "507_CR78",
      "unstructured": "Payan-Gomez C, Ramirez-Cheyne J, Saldarriaga W. Variable expressivity in fragile X syndrome: towards the identification of molecular characteristics that modify the phenotype. Appl Clin Genet. 2021;14:305–12.",
      "volume": "14",
      "year": "2021"
    },
    {
      "DOI": "10.1002/ajmg.1320510444",
      "author": "SL Nolin",
      "doi-asserted-by": "publisher",
      "first-page": "509",
      "issue": "4",
      "journal-title": "Am J Med Genet",
      "key": "507_CR79",
      "unstructured": "Nolin SL, Glicksman A, Houck GE Jr, Brown WT, Dobkin CS. Mosaicism in fragile X affected males. Am J Med Genet. 1994;51(4):509–12.",
      "volume": "51",
      "year": "1994"
    },
    {
      "DOI": "10.1371/journal.pone.0023648",
      "author": "R Stöger",
      "doi-asserted-by": "publisher",
      "first-page": "e23648",
      "issue": "8",
      "journal-title": "PLoS ONE",
      "key": "507_CR80",
      "unstructured": "Stöger R, Genereux DP, Hagerman RJ, Hagerman PJ, Tassone F, Laird CD. Testing the FMR1 promoter for mosaicism in DNA methylation among CpG sites, strands, and cells in FMR1-expressing males with fragile X syndrome. PLoS ONE. 2011;6(8):e23648.",
      "volume": "6",
      "year": "2011"
    },
    {
      "DOI": "10.1038/ejhg.2013.311",
      "author": "LK Myrick",
      "doi-asserted-by": "publisher",
      "first-page": "1185",
      "issue": "10",
      "journal-title": "Eur J Hum Genet",
      "key": "507_CR81",
      "unstructured": "Myrick LK, Nakamoto-Kinoshita M, Lindor NM, Kirmani S, Cheng X, Warren ST. Fragile X syndrome due to a missense mutation. Eur J Hum Genet. 2014;22(10):1185–9.",
      "volume": "22",
      "year": "2014"
    },
    {
      "DOI": "10.1038/ejhg.2016.204",
      "author": "A Quartier",
      "doi-asserted-by": "publisher",
      "first-page": "423",
      "issue": "4",
      "journal-title": "Eur J Hum Genet",
      "key": "507_CR82",
      "unstructured": "Quartier A, Poquet H, Gilbert-Dussardier B, Rossi M, Casteleyn AS, Portes VD, Feger C, Nourisson E, Kuentz P, Redin C, et al. Intragenic FMR1 disease-causing variants: a significant mutational mechanism leading to Fragile-X syndrome. Eur J Hum Genet. 2017;25(4):423–31.",
      "volume": "25",
      "year": "2017"
    },
    {
      "DOI": "10.3390/brainsci10100694",
      "doi-asserted-by": "crossref",
      "key": "507_CR83",
      "unstructured": "Budimirovic DB, Schlageter A, Filipovic-Sadic S, Protic DD, Bram E, Mahone EM, Nicholson K, Culp K, Javanmardi K, Kemppainen J, et al. A Genotype-phenotype study of high-resolution FMR1 nucleic acid and protein analyses in Fragile X patients with neurobehavioral aAssessments. Brain Sci. 2020;10(10)."
    },
    {
      "DOI": "10.4088/PCC.12l01492",
      "doi-asserted-by": "crossref",
      "key": "507_CR84",
      "unstructured": "Schneider A, Seritan A, Tassone F, Rivera SM, Hagerman R, Hessl D. Psychiatric features in high-functioning adult brothers with fragile x spectrum disorders. Prim Care Companion CNS Disord. 2013;15(2)."
    },
    {
      "DOI": "10.1002/(SICI)1096-8628(19990528)84:3\u003c221::AID-AJMG11\u003e3.0.CO;2-M",
      "author": "B Schmucker",
      "doi-asserted-by": "publisher",
      "first-page": "221",
      "issue": "3",
      "journal-title": "Am J Med Genet",
      "key": "507_CR85",
      "unstructured": "Schmucker B, Seidel J. Mosaicism for a full mutation and a normal size allele in two fragile X males. Am J Med Genet. 1999;84(3):221–5.",
      "volume": "84",
      "year": "1999"
    },
    {
      "DOI": "10.1002/ajmg.a.37163",
      "author": "Z Stark",
      "doi-asserted-by": "publisher",
      "first-page": "2485",
      "issue": "10",
      "journal-title": "Am J Med Genet A",
      "key": "507_CR86",
      "unstructured": "Stark Z, Francis D, Gaffney L, Greenberg J, Hills L, Li X, Godler DE, Slater HR. Prenatal diagnosis of fragile X syndrome complicated by full mutation retraction. Am J Med Genet A. 2015;167A(10):2485–7.",
      "volume": "167A",
      "year": "2015"
    },
    {
      "DOI": "10.1186/s11689-019-9288-7",
      "author": "EK Baker",
      "doi-asserted-by": "publisher",
      "first-page": "41",
      "issue": "1",
      "journal-title": "J Neurodev Disord",
      "key": "507_CR87",
      "unstructured": "Baker EK, Arpone M, Vera SA, Bretherton L, Ure A, Kraan CM, Bui M, Ling L, Francis D, Hunter MF, et al. Intellectual functioning and behavioural features associated with mosaicism in fragile X syndrome. J Neurodev Disord. 2019;11(1):41.",
      "volume": "11",
      "year": "2019"
    },
    {
      "DOI": "10.1126/science.aad5143",
      "author": "CE Nelson",
      "doi-asserted-by": "publisher",
      "first-page": "403",
      "issue": "6271",
      "journal-title": "Science",
      "key": "507_CR88",
      "unstructured": "Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351(6271):403–7.",
      "volume": "351",
      "year": "2016"
    },
    {
      "DOI": "10.1126/science.1245831",
      "author": "D Colak",
      "doi-asserted-by": "publisher",
      "first-page": "1002",
      "issue": "6174",
      "journal-title": "Science",
      "key": "507_CR89",
      "unstructured": "Colak D, Zaninovic N, Cohen MS, Rosenwaks Z, Yang WY, Gerhardt J, Disney MD, Jaffrey SR. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science. 2014;343(6174):1002–5.",
      "volume": "343",
      "year": "2014"
    },
    {
      "DOI": "10.1002/1096-8628(20000918)94:3\u003c232::AID-AJMG9\u003e3.0.CO;2-H",
      "author": "F Tassone",
      "doi-asserted-by": "publisher",
      "first-page": "232",
      "issue": "3",
      "journal-title": "Am J Med Genet",
      "key": "507_CR90",
      "unstructured": "Tassone F, Hagerman RJ, Loesch DZ, Lachiewicz A, Taylor AK, Hagerman PJ. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet. 2000;94(3):232–6.",
      "volume": "94",
      "year": "2000"
    },
    {
      "DOI": "10.1017/S1355838202020642",
      "author": "B Primerano",
      "doi-asserted-by": "publisher",
      "first-page": "1482",
      "issue": "12",
      "journal-title": "RNA",
      "key": "507_CR91",
      "unstructured": "Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA. 2002;8(12):1482–8.",
      "volume": "8",
      "year": "2002"
    },
    {
      "DOI": "10.1016/j.ncrna.2020.11.006",
      "author": "AA Dolskiy",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Noncoding RNA Res",
      "key": "507_CR92",
      "unstructured": "Dolskiy AA, Yarushkin AA, Grishchenko IV, Lemskaya NA, Pindyurin AV, Boldyreva LV, Pustylnyak VO, Yudkin DV. miRNA expression and interaction with the 3’UTR of FMR1 in FRAXopathy pathogenesis. Noncoding RNA Res. 2021;6(1):1–7.",
      "volume": "6",
      "year": "2021"
    },
    {
      "DOI": "10.1136/jmedgenet-2013-102021",
      "author": "DI Pretto",
      "doi-asserted-by": "publisher",
      "first-page": "309",
      "issue": "5",
      "journal-title": "J Med Genet",
      "key": "507_CR93",
      "unstructured": "Pretto DI, Mendoza-Morales G, Lo J, Cao R, Hadd A, Latham GJ, Durbin-Johnson B, Hagerman R, Tassone F. CGG allele size somatic mosaicism and methylation in FMR1 premutation alleles. J Med Genet. 2014;51(5):309–18.",
      "volume": "51",
      "year": "2014"
    },
    {
      "DOI": "10.1080/14737159.2017.1377612",
      "author": "P Jiraanont",
      "doi-asserted-by": "publisher",
      "first-page": "1023",
      "issue": "11",
      "journal-title": "Expert Rev Mol Diagn",
      "key": "507_CR94",
      "unstructured": "Jiraanont P, Kumar M, Tang HT, Espinal G, Hagerman PJ, Hagerman RJ, Chutabhakdikul N, Tassone F. Size and methylation mosaicism in males with Fragile X syndrome. Expert Rev Mol Diagn. 2017;17(11):1023–32.",
      "volume": "17",
      "year": "2017"
    },
    {
      "DOI": "10.1002/ajmg.a.63027",
      "author": "EK Baker",
      "doi-asserted-by": "publisher",
      "first-page": "357",
      "issue": "2",
      "journal-title": "Am J Med Genet A",
      "key": "507_CR95",
      "unstructured": "Baker EK, Arpone M, Bui M, Kraan CM, Ling L, Francis D, Hunter MF, Rogers C, Field MJ, Santa Maria L, et al. Tissue mosaicism, FMR1 expression and intellectual functioning in males with fragile X syndrome. Am J Med Genet A. 2023;191(2):357–69.",
      "volume": "191",
      "year": "2023"
    },
    {
      "DOI": "10.1186/s40246-022-00398-9",
      "author": "NA Elhawary",
      "doi-asserted-by": "publisher",
      "first-page": "22",
      "issue": "1",
      "journal-title": "Hum Genomics",
      "key": "507_CR96",
      "unstructured": "Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, Madkhali A, Alosaimi W, Alzahrani A, Aljohani F, et al. Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics. 2022;16(1):22.",
      "volume": "16",
      "year": "2022"
    },
    {
      "DOI": "10.1086/302938",
      "author": "KM Dipple",
      "doi-asserted-by": "publisher",
      "first-page": "1729",
      "issue": "6",
      "journal-title": "Am J Hum Genet",
      "key": "507_CR97",
      "unstructured": "Dipple KM, McCabe ER. Phenotypes of patients with “simple” Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet. 2000;66(6):1729–35.",
      "volume": "66",
      "year": "2000"
    },
    {
      "DOI": "10.1136/jmedgenet-2013-101713",
      "author": "AA Schaffer",
      "doi-asserted-by": "publisher",
      "first-page": "641",
      "issue": "10",
      "journal-title": "J Med Genet",
      "key": "507_CR98",
      "unstructured": "Schaffer AA. Digenic inheritance in medical genetics. J Med Genet. 2013;50(10):641–52.",
      "volume": "50",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.eplepsyres.2009.01.005",
      "author": "V Louhivuori",
      "doi-asserted-by": "publisher",
      "first-page": "114",
      "issue": "1",
      "journal-title": "Epilepsy Res",
      "key": "507_CR99",
      "unstructured": "Louhivuori V, Arvio M, Soronen P, Oksanen V, Paunio T, Castren ML. The Val66Met polymorphism in the BDNF gene is associated with epilepsy in fragile X syndrome. Epilepsy Res. 2009;85(1):114–7.",
      "volume": "85",
      "year": "2009"
    },
    {
      "DOI": "10.15252/emmm.201505696",
      "author": "B Stepniak",
      "doi-asserted-by": "publisher",
      "first-page": "1565",
      "issue": "12",
      "journal-title": "EMBO Mol Med",
      "key": "507_CR100",
      "unstructured": "Stepniak B, Kastner A, Poggi G, Mitjans M, Begemann M, Hartmann A, Van der Auwera S, Sananbenesi F, Krueger-Burg D, Matuszko G, et al. Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes. EMBO Mol Med. 2015;7(12):1565–79.",
      "volume": "7",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.yebeh.2011.08.003",
      "author": "M Tondo",
      "doi-asserted-by": "publisher",
      "first-page": "581",
      "issue": "3",
      "journal-title": "Epilepsy Behav",
      "key": "507_CR101",
      "unstructured": "Tondo M, Poo P, Naudo M, Ferrando T, Genoves J, Molero M, Martorell L. Predisposition to epilepsy in fragile X syndrome: does the Val66Met polymorphism in the BDNF gene play a role? Epilepsy Behav. 2011;22(3):581–3.",
      "volume": "22",
      "year": "2011"
    },
    {
      "DOI": "10.1186/1866-1955-6-6",
      "author": "TH Wassink",
      "doi-asserted-by": "publisher",
      "first-page": "6",
      "issue": "1",
      "journal-title": "J Neurodev Disord",
      "key": "507_CR102",
      "unstructured": "Wassink TH, Hazlett HC, Davis LK, Reiss AL, Piven J. Testing for association of the monoamine oxidase A promoter polymorphism with brain structure volumes in both autism and the fragile X syndrome. J Neurodev Disord. 2014;6(1):6.",
      "volume": "6",
      "year": "2014"
    },
    {
      "DOI": "10.1038/s41431-020-00711-x",
      "author": "H Crawford",
      "doi-asserted-by": "publisher",
      "first-page": "173",
      "issue": "1",
      "journal-title": "Eur J Hum Genet",
      "key": "507_CR103",
      "unstructured": "Crawford H, Scerif G, Wilde L, Beggs A, Stockton J, Sandhu P, Shelley L, Oliver C, McCleery J. Genetic modifiers in rare disorders: the case of fragile X syndrome. Eur J Hum Genet. 2021;29(1):173–83.",
      "volume": "29",
      "year": "2021"
    },
    {
      "DOI": "10.1038/sj.mp.4001656",
      "author": "PR Szeszko",
      "doi-asserted-by": "publisher",
      "first-page": "631",
      "issue": "7",
      "journal-title": "Mol Psychiatry",
      "key": "507_CR104",
      "unstructured": "Szeszko PR, Lipsky R, Mentschel C, Robinson D, Gunduz-Bruce H, Sevy S, Ashtari M, Napolitano B, Bilder RM, Kane JM, et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry. 2005;10(7):631–6.",
      "volume": "10",
      "year": "2005"
    },
    {
      "DOI": "10.1126/science.1129663",
      "author": "ZY Chen",
      "doi-asserted-by": "publisher",
      "first-page": "140",
      "issue": "5796",
      "journal-title": "Science",
      "key": "507_CR105",
      "unstructured": "Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314(5796):140–3.",
      "volume": "314",
      "year": "2006"
    },
    {
      "DOI": "10.1016/j.biopsych.2006.08.025",
      "author": "M Gratacos",
      "doi-asserted-by": "publisher",
      "first-page": "911",
      "issue": "7",
      "journal-title": "Biol Psychiatry",
      "key": "507_CR106",
      "unstructured": "Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry. 2007;61(7):911–22.",
      "volume": "61",
      "year": "2007"
    },
    {
      "DOI": "10.2147/NDT.S230348",
      "author": "AH Arab",
      "doi-asserted-by": "publisher",
      "first-page": "3569",
      "journal-title": "Neuropsychiatr Dis Treat",
      "key": "507_CR107",
      "unstructured": "Arab AH, Elhawary NA. Methylenetetrahydrofolate reductase gene variants confer potential vulnerability to Autism Spectrum Disorder in a Saudi Community. Neuropsychiatr Dis Treat. 2019;15:3569–81.",
      "volume": "15",
      "year": "2019"
    },
    {
      "DOI": "10.1007/s10803-007-0365-5",
      "author": "D Hessl",
      "doi-asserted-by": "publisher",
      "first-page": "184",
      "issue": "1",
      "journal-title": "J Autism Dev Disord",
      "key": "507_CR108",
      "unstructured": "Hessl D, Tassone F, Cordeiro L, Koldewyn K, McCormick C, Green C, Wegelin J, Yuhas J, Hagerman RJ. Brief report: aggression and stereotypic behavior in males with fragile X syndrome–moderating secondary genes in a “single gene” disorder. J Autism Dev Disord. 2008;38(1):184–9.",
      "volume": "38",
      "year": "2008"
    },
    {
      "DOI": "10.3390/brainsci8120214",
      "doi-asserted-by": "crossref",
      "key": "507_CR109",
      "unstructured": "Lee AW, Ventola P, Budimirovic D, Berry-Kravis E, Visootsak J. Clinical development of targeted fragile X syndrome treatments: an industry perspective. Brain Sci. 2018;8(12)."
    },
    {
      "DOI": "10.1007/s00439-017-1840-5",
      "author": "BE Hayward",
      "doi-asserted-by": "publisher",
      "first-page": "1313",
      "issue": "10",
      "journal-title": "Hum Genet",
      "key": "507_CR110",
      "unstructured": "Hayward BE, Kumari D, Usdin K. Recent advances in assays for the fragile X-related disorders. Hum Genet. 2017;136(10):1313–27.",
      "volume": "136",
      "year": "2017"
    },
    {
      "DOI": "10.2353/jmoldx.2008.070073",
      "author": "F Tassone",
      "doi-asserted-by": "publisher",
      "first-page": "43",
      "issue": "1",
      "journal-title": "J Mol Diagn",
      "key": "507_CR111",
      "unstructured": "Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008;10(1):43–9.",
      "volume": "10",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.jmoldx.2016.06.005",
      "author": "LC Schenkel",
      "doi-asserted-by": "publisher",
      "first-page": "834",
      "issue": "6",
      "journal-title": "J Mol Diagn",
      "key": "507_CR112",
      "unstructured": "Schenkel LC, Schwartz C, Skinner C, Rodenhiser DI, Ainsworth PJ, Pare G, Sadikovic B. Clinical validation of Fragile X syndrome screening by DNA methylation array. J Mol Diagn. 2016;18(6):834–41.",
      "volume": "18",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.cell.2018.01.012",
      "author": "XS Liu",
      "doi-asserted-by": "publisher",
      "first-page": "979",
      "issue": "5",
      "journal-title": "Cell",
      "key": "507_CR113",
      "unstructured": "Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, Hnisz D, Li CH, Yuan B, Xu C, et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell. 2018;172(5):979-92 e6.",
      "volume": "172",
      "year": "2018"
    },
    {
      "DOI": "10.1002/mgg3.398",
      "author": "TK Lubala",
      "doi-asserted-by": "publisher",
      "first-page": "526",
      "issue": "4",
      "journal-title": "Mol Genet Genom Med",
      "key": "507_CR114",
      "unstructured": "Lubala TK, Lumaka A, Kanteng G, Mutesa L, Mukuku O, Wembonyama S, Hagerman R, Luboya ON, Lukusa TP. Fragile X checklists: A meta-analysis and development of a simplified universal clinical checklist. Mol Genet Genom Med. 2018;6(4):526–32.",
      "volume": "6",
      "year": "2018"
    },
    {
      "DOI": "10.3389/fnsyn.2017.00015",
      "author": "S Castagnola",
      "doi-asserted-by": "publisher",
      "first-page": "15",
      "journal-title": "Front Synaptic Neurosci",
      "key": "507_CR115",
      "unstructured": "Castagnola S, Bardoni B, Maurin T. The Search for an effective therapy to treat fragile X syndrome: Dream or reality? Front Synaptic Neurosci. 2017;9:15.",
      "volume": "9",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s11689-022-09466-6",
      "author": "E Berry-Kravis",
      "doi-asserted-by": "publisher",
      "first-page": "56",
      "issue": "1",
      "journal-title": "J Neurodev Disord",
      "key": "507_CR116",
      "unstructured": "Berry-Kravis E, Hagerman R, Budimirovic D, Erickson C, Heussler H, Tartaglia N, et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). J Neurodev Disord. 2022;14(1):56.",
      "volume": "14",
      "year": "2022"
    },
    {
      "DOI": "10.1016/j.jpsychires.2014.07.011",
      "author": "CA Erickson",
      "doi-asserted-by": "publisher",
      "first-page": "220",
      "journal-title": "J Psychiatr Res",
      "key": "507_CR117",
      "unstructured": "Erickson CA, Ray B, Maloney B, Wink LK, Bowers K, Schaefer TL, McDougle CJ, Sokol DK, Lahiri DK. Impact of acamprosate on plasma amyloid-beta precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res. 2014;59:220–8.",
      "volume": "59",
      "year": "2014"
    },
    {
      "DOI": "10.1111/cge.13039",
      "author": "ABC Dy",
      "doi-asserted-by": "publisher",
      "first-page": "216",
      "issue": "2",
      "journal-title": "Clin Genet",
      "key": "507_CR118",
      "unstructured": "Dy ABC, Tassone F, Eldeeb M, Salcedo-Arellano MJ, Tartaglia N, Hagerman R. Metformin as targeted treatment in fragile X syndrome. Clin Genet. 2018;93(2):216–22.",
      "volume": "93",
      "year": "2018"
    },
    {
      "DOI": "10.1186/s11689-023-09475-z",
      "author": "JM Palumbo",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "J Neurodev Disord",
      "key": "507_CR119",
      "unstructured": "Palumbo JM, Thomas BF, Budimirovic D, Siegel S, Tassone F, Hagerman R, Faulk C, O’Quinn S, Sebree T. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. J Neurodev Disord. 2023;15(1):1.",
      "volume": "15",
      "year": "2023"
    },
    {
      "DOI": "10.1038/nm.4335",
      "author": "I Gantois",
      "doi-asserted-by": "publisher",
      "first-page": "674",
      "issue": "6",
      "journal-title": "Nat Med",
      "key": "507_CR120",
      "unstructured": "Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R, Sharma V, Pooters T, Nagpal A, Skalecka A, et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med. 2017;23(6):674–7.",
      "volume": "23",
      "year": "2017"
    },
    {
      "DOI": "10.1038/nrneurol.2017.82",
      "author": "H Wood",
      "doi-asserted-by": "publisher",
      "first-page": "384",
      "issue": "7",
      "journal-title": "Nat Rev Neurol",
      "key": "507_CR121",
      "unstructured": "Wood H. Neurodevelopmental disorders: Metformin - a therapeutic option for fragile X syndrome? Nat Rev Neurol. 2017;13(7):384–5.",
      "volume": "13",
      "year": "2017"
    },
    {
      "DOI": "10.3389/fneur.2020.581429",
      "author": "A Rajaratnam",
      "doi-asserted-by": "publisher",
      "first-page": "581429",
      "journal-title": "Front Neurol",
      "key": "507_CR122",
      "unstructured": "Rajaratnam A, Potter LA, Biag HMB, Schneider A, Petrasic IC, Hagerman RJ. Review of autism profiles and response to sertraline in fragile x syndrome-associated autism vs. non-syndromic autism; Next steps for targeted treatment. Front Neurol. 2020;11:581429.",
      "volume": "11",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s10803-013-1943-3",
      "author": "CA Erickson",
      "doi-asserted-by": "publisher",
      "first-page": "981",
      "issue": "4",
      "journal-title": "J Autism Dev Disord",
      "key": "507_CR123",
      "unstructured": "Erickson CA, Wink LK, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, McDougle CJ. Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. J Autism Dev Disord. 2014;44(4):981–7.",
      "volume": "44",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.ejphar.2010.08.026",
      "author": "Y Kitaichi",
      "doi-asserted-by": "publisher",
      "first-page": "90",
      "issue": "1–3",
      "journal-title": "Eur J Pharmacol",
      "key": "507_CR124",
      "unstructured": "Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol. 2010;647(1–3):90–6.",
      "volume": "647",
      "year": "2010"
    },
    {
      "DOI": "10.1097/YCO.0000000000000131",
      "author": "RJ Hagerman",
      "doi-asserted-by": "publisher",
      "first-page": "107",
      "issue": "2",
      "journal-title": "Curr Opin Psychiatry",
      "key": "507_CR125",
      "unstructured": "Hagerman RJ, Polussa J. Treatment of the psychiatric problems associated with fragile X syndrome. Curr Opin Psychiatry. 2015;28(2):107–12.",
      "volume": "28",
      "year": "2015"
    },
    {
      "DOI": "10.1186/2040-2392-4-16",
      "author": "L Boccuto",
      "doi-asserted-by": "publisher",
      "first-page": "16",
      "issue": "1",
      "journal-title": "Mol Autism",
      "key": "507_CR126",
      "unstructured": "Boccuto L, Chen CF, Pittman AR, Skinner CD, McCartney HJ, Jones K, Bochner BR, Stevenson RE, Schwartz CE. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism. 2013;4(1):16.",
      "volume": "4",
      "year": "2013"
    },
    {
      "DOI": "10.5582/irdr.2014.01027",
      "author": "AC Hanson",
      "doi-asserted-by": "publisher",
      "first-page": "110",
      "issue": "4",
      "journal-title": "Intractable Rare Dis Res",
      "key": "507_CR127",
      "unstructured": "Hanson AC, Hagerman RJ. Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable Rare Dis Res. 2014;3(4):110–7.",
      "volume": "3",
      "year": "2014"
    },
    {
      "DOI": "10.1002/jnr.21273",
      "author": "IM Ethell",
      "doi-asserted-by": "publisher",
      "first-page": "2813",
      "issue": "13",
      "journal-title": "J Neurosci Res",
      "key": "507_CR128",
      "unstructured": "Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res. 2007;85(13):2813–23.",
      "volume": "85",
      "year": "2007"
    },
    {
      "DOI": "10.1002/ajmg.a.36023",
      "author": "M Dziembowska",
      "doi-asserted-by": "publisher",
      "first-page": "1897",
      "issue": "8",
      "journal-title": "Am J Med Genet A",
      "key": "507_CR129",
      "unstructured": "Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A. 2013;161A(8):1897–903.",
      "volume": "161A",
      "year": "2013"
    },
    {
      "DOI": "10.1038/nn.3379",
      "author": "JC Darnell",
      "doi-asserted-by": "publisher",
      "first-page": "1530",
      "issue": "11",
      "journal-title": "Nat Neurosci",
      "key": "507_CR130",
      "unstructured": "Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci. 2013;16(11):1530–6.",
      "volume": "16",
      "year": "2013"
    },
    {
      "DOI": "10.1523/JNEUROSCI.1162-14.2014",
      "author": "H Sidhu",
      "doi-asserted-by": "publisher",
      "first-page": "9867",
      "issue": "30",
      "journal-title": "J Neurosci",
      "key": "507_CR131",
      "unstructured": "Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci. 2014;34(30):9867–79.",
      "volume": "34",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.neuron.2012.01.034",
      "author": "EK Osterweil",
      "doi-asserted-by": "publisher",
      "first-page": "243",
      "issue": "2",
      "journal-title": "Neuron",
      "key": "507_CR132",
      "unstructured": "Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, Bear MF. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron. 2013;77(2):243–50.",
      "volume": "77",
      "year": "2013"
    },
    {
      "DOI": "10.1186/s11689-020-09315-4",
      "author": "AJ Thurman",
      "doi-asserted-by": "publisher",
      "first-page": "12",
      "issue": "1",
      "journal-title": "J Neurodev Disord",
      "key": "507_CR133",
      "unstructured": "Thurman AJ, Potter LA, Kim K, Tassone F, Banasik A, Potter SN, et al. Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. J Neurodev Disord. 2020;12(1):12.",
      "volume": "12",
      "year": "2020"
    },
    {
      "DOI": "10.1089/cap.2011.0034",
      "author": "CA Erickson",
      "doi-asserted-by": "publisher",
      "first-page": "565",
      "issue": "6",
      "journal-title": "J Child Adolesc Psychopharmacol",
      "key": "507_CR134",
      "unstructured": "Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21(6):565–9.",
      "volume": "21",
      "year": "2011"
    },
    {
      "DOI": "10.2174/1573396315666190625110748",
      "author": "D Protic",
      "doi-asserted-by": "publisher",
      "first-page": "251",
      "issue": "4",
      "journal-title": "Curr Pediatr Rev",
      "key": "507_CR135",
      "unstructured": "Protic D, Salcedo-Arellano MJ, Dy JB, Potter LA, Hagerman RJ. New targeted treatments for fragile X syndrome. Curr Pediatr Rev. 2019;15(4):251–8.",
      "volume": "15",
      "year": "2019"
    },
    {
      "DOI": "10.1007/s00415-016-8145-9",
      "author": "JL Lopez-Sendon Moreno",
      "doi-asserted-by": "publisher",
      "first-page": "1390",
      "issue": "7",
      "journal-title": "J Neurol",
      "key": "507_CR136",
      "unstructured": "Lopez-Sendon Moreno JL, Garcia Caldentey J, Trigo Cubillo P, Ruiz Romero C, Garcia Ribas G, Alonso Arias MA, Garcia de Yebenes MJ, Tolon RM, Galve-Roperh I, Sagredo O, et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J Neurol. 2016;263(7):1390–400.",
      "volume": "263",
      "year": "2016"
    },
    {
      "DOI": "10.3389/fimmu.2018.02009",
      "author": "JA Crippa",
      "doi-asserted-by": "publisher",
      "first-page": "2009",
      "journal-title": "Front Immunol",
      "key": "507_CR137",
      "unstructured": "Crippa JA, Guimaraes FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of Cannabidiol (CBD): toward a new age. Front Immunol. 2018;9:2009.",
      "volume": "9",
      "year": "2018"
    },
    {
      "DOI": "10.3389/fpsyt.2021.643442",
      "author": "KA Kwan Cheung",
      "doi-asserted-by": "publisher",
      "first-page": "643442",
      "journal-title": "Front Psychiatry",
      "key": "507_CR138",
      "unstructured": "Kwan Cheung KA, Mitchell MD, Heussler HS. Cannabidiol and neurodevelopmental disorders in children. Front Psychiatry. 2021;12:643442.",
      "volume": "12",
      "year": "2021"
    },
    {
      "DOI": "10.1186/1471-2377-9-53",
      "author": "JR Rueda",
      "doi-asserted-by": "publisher",
      "first-page": "53",
      "journal-title": "BMC Neurol",
      "key": "507_CR139",
      "unstructured": "Rueda JR, Ballesteros J, Tejada MI. Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurol. 2009;9:53.",
      "volume": "9",
      "year": "2009"
    },
    {
      "DOI": "10.1002/ajmg.a.32268",
      "author": "MG Torrioli",
      "doi-asserted-by": "publisher",
      "first-page": "803",
      "issue": "7",
      "journal-title": "Am J Med Genet A",
      "key": "507_CR140",
      "unstructured": "Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008;146A(7):803–12.",
      "volume": "146A",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.neuropharm.2005.06.004",
      "author": "QJ Yan",
      "doi-asserted-by": "publisher",
      "first-page": "1053",
      "issue": "7",
      "journal-title": "Neuropharmacology",
      "key": "507_CR141",
      "unstructured": "Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005;49(7):1053–66.",
      "volume": "49",
      "year": "2005"
    },
    {
      "DOI": "10.1007/s00213-010-2130-2",
      "author": "T Su",
      "doi-asserted-by": "publisher",
      "first-page": "291",
      "issue": "2",
      "journal-title": "Psychopharmacology",
      "key": "507_CR142",
      "unstructured": "Su T, Fan HX, Jiang T, Sun WW, Den WY, Gao MM, Chen SQ, Zhao QH, Yi YH. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology. 2011;215(2):291–300.",
      "volume": "215",
      "year": "2011"
    },
    {
      "DOI": "10.1111/jir.12234",
      "author": "A Oakes",
      "doi-asserted-by": "publisher",
      "first-page": "54",
      "issue": "1",
      "journal-title": "J Intellect Disabil Res",
      "key": "507_CR143",
      "unstructured": "Oakes A, Thurman AJ, McDuffie A, Bullard LM, Hagerman RJ, Abbeduto L. Characterising repetitive behaviours in young boys with fragile X syndrome. J Intellect Disabil Res. 2016;60(1):54–67.",
      "volume": "60",
      "year": "2016"
    },
    {
      "DOI": "10.1111/j.1601-183X.2005.00135.x",
      "author": "MF Bear",
      "doi-asserted-by": "publisher",
      "first-page": "393",
      "issue": "6",
      "journal-title": "Genes Brain Behav",
      "key": "507_CR144",
      "unstructured": "Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. 2005;4(6):393–8.",
      "volume": "4",
      "year": "2005"
    },
    {
      "DOI": "10.1038/nrneurol.2017.148",
      "author": "C Rinaldi",
      "doi-asserted-by": "publisher",
      "first-page": "9",
      "issue": "1",
      "journal-title": "Nat Rev Neurol",
      "key": "507_CR145",
      "unstructured": "Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9–21.",
      "volume": "14",
      "year": "2018"
    },
    {
      "DOI": "10.1038/s41573-019-0017-4",
      "author": "RL Setten",
      "doi-asserted-by": "publisher",
      "first-page": "421",
      "issue": "6",
      "journal-title": "Nat Rev Drug Discov",
      "key": "507_CR146",
      "unstructured": "Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–46.",
      "volume": "18",
      "year": "2019"
    },
    {
      "DOI": "10.1126/science.1231143",
      "author": "L Cong",
      "doi-asserted-by": "publisher",
      "first-page": "819",
      "issue": "6121",
      "journal-title": "Science",
      "key": "507_CR147",
      "unstructured": "Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–23.",
      "volume": "339",
      "year": "2013"
    },
    {
      "DOI": "10.1126/science.1232033",
      "author": "P Mali",
      "doi-asserted-by": "publisher",
      "first-page": "823",
      "issue": "6121",
      "journal-title": "Science",
      "key": "507_CR148",
      "unstructured": "Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–6.",
      "volume": "339",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.cell.2014.09.029",
      "author": "LA Gilbert",
      "doi-asserted-by": "publisher",
      "first-page": "647",
      "issue": "3",
      "journal-title": "Cell",
      "key": "507_CR149",
      "unstructured": "Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014;159(3):647–61.",
      "volume": "159",
      "year": "2014"
    },
    {
      "DOI": "10.1126/science.1225829",
      "author": "M Jinek",
      "doi-asserted-by": "publisher",
      "first-page": "816",
      "issue": "6096",
      "journal-title": "Science",
      "key": "507_CR150",
      "unstructured": "Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–21.",
      "volume": "337",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.cell.2016.10.044",
      "author": "AC Komor",
      "doi-asserted-by": "publisher",
      "first-page": "20",
      "issue": "1–2",
      "journal-title": "Cell",
      "key": "507_CR151",
      "unstructured": "Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell. 2017;168(1–2):20–36.",
      "volume": "168",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.stem.2015.07.001",
      "author": "CY Park",
      "doi-asserted-by": "publisher",
      "first-page": "213",
      "issue": "2",
      "journal-title": "Cell Stem Cell",
      "key": "507_CR152",
      "unstructured": "Park CY, Kim DH, Son JS, Sung JJ, Lee J, Bae S, Kim JH, Kim DW, Kim JS. Functional correction of large factor viii gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell. 2015;17(2):213–20.",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.1126/science.aad5725",
      "author": "C Long",
      "doi-asserted-by": "publisher",
      "first-page": "400",
      "issue": "6271",
      "journal-title": "Science",
      "key": "507_CR153",
      "unstructured": "Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, Bhattacharyya S, Shelton JM, Bassel-Duby R, Olson EN. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351(6271):400–3.",
      "volume": "351",
      "year": "2016"
    },
    {
      "DOI": "10.1126/science.aad5177",
      "author": "M Tabebordbar",
      "doi-asserted-by": "publisher",
      "first-page": "407",
      "issue": "6271",
      "journal-title": "Science",
      "key": "507_CR154",
      "unstructured": "Tabebordbar M, Zhu K, Cheng JKW, Chew WL, Widrick JJ, Yan WX, Maesner C, Wu EY, Xiao R, Ran FA, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351(6271):407–11.",
      "volume": "351",
      "year": "2016"
    },
    {
      "DOI": "10.1007/s00439-017-1801-z",
      "author": "C Huai",
      "doi-asserted-by": "publisher",
      "first-page": "875",
      "issue": "7",
      "journal-title": "Hum Genet",
      "key": "507_CR155",
      "unstructured": "Huai C, Jia C, Sun R, Xu P, Min T, Wang Q, Zheng C, Chen H, Lu D. CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice. Hum Genet. 2017;136(7):875–83.",
      "volume": "136",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.crviro.2022.100023",
      "doi-asserted-by": "crossref",
      "key": "507_CR156",
      "unstructured": "Oh HS, Diaz FM, Zhou C, Carpenter N, Knipe DM. CRISPR-Cas9 Expressed in Stably Transduced Cell Lines Promotes Recombination and Selects for Herpes Simplex Virus Recombinants. Curr Res Virol Sci. 2022;3."
    },
    {
      "DOI": "10.1038/mtna.2016.58",
      "author": "WJ Dai",
      "doi-asserted-by": "publisher",
      "first-page": "e349",
      "issue": "8",
      "journal-title": "Mol Ther Nucleic Acids",
      "key": "507_CR157",
      "unstructured": "Dai WJ, Zhu LY, Yan ZY, Xu Y, Wang QL, Lu XJ. CRISPR-Cas9 for in vivo gene therapy: promise and hurdles. Mol Ther Nucleic Acids. 2016;5(8):e349.",
      "volume": "5",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nature25164",
      "author": "X Gao",
      "doi-asserted-by": "publisher",
      "first-page": "217",
      "issue": "7687",
      "journal-title": "Nature",
      "key": "507_CR158",
      "unstructured": "Gao X, Tao Y, Lamas V, Huang M, Yeh WH, Pan B, Hu YJ, Hu JH, Thompson DB, Shu Y, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature. 2018;553(7687):217–21.",
      "volume": "553",
      "year": "2018"
    },
    {
      "DOI": "10.1021/acschembio.7b00777",
      "author": "KS Pawelczak",
      "doi-asserted-by": "publisher",
      "first-page": "389",
      "issue": "2",
      "journal-title": "ACS Chem Biol",
      "key": "507_CR159",
      "unstructured": "Pawelczak KS, Gavande NS, VanderVere-Carozza PS, Turchi JJ. Modulating DNA repair pathways to improve precision genome engineering. ACS Chem Biol. 2018;13(2):389–96.",
      "volume": "13",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.ymthe.2020.05.002",
      "author": "KA Christie",
      "doi-asserted-by": "publisher",
      "first-page": "1846",
      "issue": "8",
      "journal-title": "Mol Ther",
      "key": "507_CR160",
      "unstructured": "Christie KA, Robertson LJ, Conway C, Blighe K, DeDionisio LA, Chao-Shern C, Kowalczyk AM, Marshall J, Turnbull D, Nesbit MA, et al. Mutation-independent allele-specific editing by CRISPR-Cas9, a Novel approach to treat autosomal dominant disease. Mol Ther. 2020;28(8):1846–57.",
      "volume": "28",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.cell.2020.03.023",
      "author": "D Wang",
      "doi-asserted-by": "publisher",
      "first-page": "136",
      "issue": "1",
      "journal-title": "Cell",
      "key": "507_CR161",
      "unstructured": "Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV Vectors. Cell. 2020;181(1):136–50.",
      "volume": "181",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.cell.2013.02.022",
      "author": "LS Qi",
      "doi-asserted-by": "publisher",
      "first-page": "1173",
      "issue": "5",
      "journal-title": "Cell",
      "key": "507_CR162",
      "unstructured": "Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–83.",
      "volume": "152",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.cell.2016.09.006",
      "author": "A Amabile",
      "doi-asserted-by": "publisher",
      "first-page": "219",
      "issue": "1",
      "journal-title": "Cell",
      "key": "507_CR163",
      "unstructured": "Amabile A, Migliara A, Capasso P, Biffi M, Cittaro D, Naldini L, Lombardo A. Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. Cell. 2016;167(1):219-32 e14.",
      "volume": "167",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41598-017-06757-0",
      "author": "T Xiong",
      "doi-asserted-by": "publisher",
      "first-page": "6732",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "507_CR164",
      "unstructured": "Xiong T, Meister GE, Workman RE, Kato NC, Spellberg MJ, Turker F, Timp W, Ostermeier M, Novina CD. Targeted DNA methylation in human cells using engineered dCas9-methyltransferases. Sci Rep. 2017;7(1):6732.",
      "volume": "7",
      "year": "2017"
    },
    {
      "DOI": "10.1038/nbt.3658",
      "author": "S Morita",
      "doi-asserted-by": "publisher",
      "first-page": "1060",
      "issue": "10",
      "journal-title": "Nat Biotechnol",
      "key": "507_CR165",
      "unstructured": "Morita S, Noguchi H, Horii T, Nakabayashi K, Kimura M, Okamura K, Sakai A, Nakashima H, Hata K, Nakashima K, et al. Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions. Nat Biotechnol. 2016;34(10):1060–5.",
      "volume": "34",
      "year": "2016"
    }
  ],
  "reference-count": 165,
  "references-count": 165,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00507-2"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Phenotypic variability to medication management: an update on fragile X syndrome"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "17"
}